News | Cardiovascular Business | August 05, 2022

Industry Veterans Join Stereotaxis Commercial Leadership Team as Company Advances Robust Innovation Pipeline

Frank Van Hyfte, VP of Europe, the Middle East and Africa

Frank Van Hyfte, VP of Europe, the Middle East and Africa


August 5, 2022 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the significant enhancement of its commercial leadership team with the successful recruitment of two veterans of the medical device, surgical robotics and electrophysiology fields. 

Joining Stereotaxis are experienced commercial leaders with relevant and complementary expertise: 

  • Frank Van Hyfte is joining as Vice President of Europe, the Middle East and Africa. Van Hyfte spent over 15 years at Intuitive Surgical, the global leader in robotic surgery, between 2000 and 2016. While at Intuitive Surgical he rose in responsibility from the role of a Clinical Specialist to Director of Direct and Indirect Markets in Europe, the Middle East, India and Africa. He subsequently served in senior commercial leadership roles at Exact Imaging, EDAP TMS, and eCential Robotics. 
  • Tim Glynn is joining as Vice President, Market Development. Glynn most recently served as Vice President of Business and Market Development at Acutus Medical, an innovator in the electrophysiology mapping and ablation field. His responsibilities evolved from establishing commercial beachheads in Europe and the United States to managing product marketing, physician relationships and business partnerships. Prior to Acutus Medical, he served in senior marketing roles at Volcano Corporation, a leader in intravascular imaging for coronary and peripheral interventions.  

“We see in Stereotaxis the opportunity to build a preeminent robotic surgery company that positively transforms electrophysiology specifically and endovascular surgery more broadly,” said Van Hyfte and Glynn in a joint statement. “We join Stereotaxis at a fitting time as it establishes the product ecosystem that can allow for substantial commercial growth. We look forward to working together with the existing Stereotaxis team in building a highly impactful commercial organization.” 

The expertise of these new commercial leaders will complement Stereotaxis’ existing commercial leadership: Michael Tropea, Vice President of North America, and Casey Payne, Vice President of Asia Pacific. Tropea leads Stereotaxis’ commercial teams in North America and has been instrumental in establishing Stereotaxis’ capital sales processes, restarting capital adoption, and managing various marketing and business development initiatives. Payne leads Stereotaxis’ Asia Pacific and Global Training teams and has been central to the resurgence in commercial adoption in Asia and advancement of Stereotaxis’ strategic collaborations in China. 

“Stereotaxis has been energetically advancing a robust innovation pipeline that enables significant adoption of robotics across electrophysiology and endovascular surgery. In preparation for these product launches, we are assembling the right commercial leadership and establishing the commercial foundations for significant growth,” said David Fischel, Chairman and CEO. “We are excited to welcome Frank and Tim to the Stereotaxis team and look forward to their contributions as leaders in our efforts to pioneer endovascular robotics.”   

For more information: www.stereotaxis.com 


Related Content

News | Cardiovascular Business

March 29, 2023 — Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging ...

Home March 29, 2023
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

February was a short but busy month in the diagnostic and interventional cardiology world, with a lot of news being ...

Home March 01, 2023
Home
News | Cardiovascular Business

February 17, 2023 — Internationally recognized cardiologist in heart transplantation Jon Kobashigawa, MD, director of ...

Home February 17, 2023
Home
News | Cardiovascular Business

February 9, 2023 — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has entered into a long ...

Home February 09, 2023
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is a recap of what DAIC viewers found most interesting during the month of January: 1. A Dietary Supplement Leads ...

Home February 01, 2023
Home
News | Cardiovascular Business

January 24, 2023 — Cardiothoracic surgeon Thomas E. MacGillivray, MD, from MedStar Health, was elected President of The ...

Home January 24, 2023
Home
News | Cardiovascular Business

January 19, 2023 — The volunteers and staff of the American Heart Association and the American Stroke Association are ...

Home January 19, 2023
Home
News | Cardiovascular Business

January 19, 2023 — Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy (IVL) to treat ...

Home January 19, 2023
Home
News | Cardiovascular Business

January 11, 2023 — The Alameda, Calif.-based global healthcare company Penumbra has announced U.S. Food & Drug ...

Home January 11, 2023
Home
News | Cardiovascular Business

January 9, 2023 — CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under ...

Home January 09, 2023
Home
Subscribe Now